Oligomerix Awarded a Grant for its Alzheimer’s Drug Discovery Program Targeting Tau Oligomers from the National Institutes of Health

NEW YORK–(BUSINESS WIRE)–Oligomerix,
Inc., a privately held company targeting tau oligomers for
developing disease modifying therapeutics for Alzheimer’s disease (AD)
and related neurodegenerative disorders, announced today the receipt of
an award for a Direct-to-Phase-II Small Business Innovation Research
(SBIR) grant for a two year program for a total of $1.5 M from the
National Institutes of Health (NIH), National Institute on Aging (NIA).
This Direct-to-Phase II SBIR program is designed to advance the
Company’s small molecule lead compounds inhibiting the formation of tau
oligomers, the acutely toxic aggregates of tau that also play an
important role in AD progression. Oligomerix will be working in close
collaboration with Alzheimer’s expert Peter Davies, Ph.D., Director,
Litwin-Zucker Center for Research on Alzheimer’s Disease, The Feinstein
Institute for Medical Research, Northwell Health. The compounds will be
tested in the human tau (htau) mouse model that was developed in the
laboratory of Dr. Davies and best represents tau pathology in AD.
“Development of a disease-modifying therapy for AD patients is an urgent
medical priority. We’re grateful for the NIH support and its scientific
approval of our program targeting tau oligomers for drug discovery for
AD. We are privileged to be working closely with Dr. Davies, a renowned
leader in tau biology. This project aims to validate our drug discovery
approach in vivo to enable selection of candidates for clinical
development,” said James Moe, Ph.D., MBA, Oligomerix’s President and
CEO, and principal investigator on the SBIR grant.
ABOUT OLIGOMERIX
Oligomerix, Inc. is a biopharmaceutical company based in New York
focused on the discovery and development of small molecule inhibitors
targeting tau oligomers and associated biomarkers. The Company is
seeking strategic partners and investors to help accelerate these
exciting programs. For more information, visit www.oligomerix.com.
Certain matters described in this news release may be forward-looking
statements subject to risks and uncertainties that could cause actual
results to differ materially from those indicated in the forward-looking
statements. Such risks and uncertainties include, but are not limited
to, the risk of dependence on market growth, competition and dependence
on government agencies and other third parties for funding contract
research and services.